Loading data for SVRA — first visit, this takes a few seconds.
Savara Inc. (SVRA)
NasdaqGS: SVRA
· Real-Time Price · USD
5.46
+0.11 (2.06%)
At close: Sep 03, 2026, 8:00 PM
5.37
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Savara Inc. (SVRA) Stock Price, Analysis & Data
No data available
| Bid | 3.89 |
| Market Cap | 1.1B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -139M |
| 0.26 | |
| -0.58 | |
| n/a | |
| -17.21 | |
| P/B (ttm) | 7.74 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 11, 2026 |
| Ask | 6.89 |
| Volume | 1,216,845 |
| Avg. Volume (20D) | 1,783,476 |
| Open | 5.40 |
| Previous Close | 5.35 |
| Day's Range | 5.37 - 5.56 |
| 52-Week Range | 3.34 - 7.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania....
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 70
Stock Exchange NasdaqGS
Ticker Symbol SVRA
Website https://www.savarapharma.com
Financial Performance
In 2025, Savara's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -118.84M, an increase of 23.94%.
Financial StatementsEarnings Surprise
Savara has released their quarterly earnings on Aug 11, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.16 misses estimates by -0.01, with -33.33% YoY decline.
Savara Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2